Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -11.19
- Piotroski Score 4.00
- Grade Buy
- Symbol (IVVD)
- Company Invivyd, Inc.
- Price $0.70
- Changes Percentage (-0.57%)
- Change -$0
- Day Low $0.69
- Day High $0.73
- Year High $5.20
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $9.50
- High Stock Price Target $10.00
- Low Stock Price Target $9.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.87
- Trailing P/E Ratio -0.9
- Forward P/E Ratio -0.9
- P/E Growth -0.9
- Net Income $-198,643,000
Income Statement
Quarterly
Annual
Latest News of IVVD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future
Invivyd, Inc., a biopharmaceutical company, is nearing a breakthrough with a predicted breakeven in 2025. Analysts forecast a profit of US$58m in 2026, requiring a 70% annual growth rate....
By Yahoo! Finance | 4 months ago
